You are here

  • Home
  • Archive
  • Volume 75, Issue 10
  • Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Authors

  • Jeffrey R Curtis Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA PubMed articlesGoogle scholar articles
  • Fenglong Xie Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA PubMed articlesGoogle scholar articles
  • Huifeng Yun Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA PubMed articlesGoogle scholar articles
  • Sasha Bernatsky Division of Clinical Epidemiology McGill University Health Centre, Montreal, Quebec, Canada PubMed articlesGoogle scholar articles
  • Kevin L Winthrop Divisions of Infectious Diseases, Public Health, and Preventive Medicine, Oregon Health & Science University, Portland, Oregon, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jeffrey R Curtis, FOT 802, 510 20th Street South, Birmingham 35294, USA; jcurtis{at}uab.edu
View Full Text

Citation

Curtis JR, Xie F, Yun H, et al
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Annals of the Rheumatic Diseases 2016;75:1843-1847.

Publication history

  • Received January 4, 2016
  • Revised February 22, 2016
  • Accepted March 3, 2016
  • First published April 25, 2016.
Online issue publication 
August 10, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/